title: Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.
abstract: Dabigatran etexilate (BIBR-1048, Rendix), an orally active prodrug of the thrombin inhibitor dabigatran (BIBR-953ZW), is being developed by Boehringer Ingelheim Corp as a potential antithrombotic agent. By March 2003, the compound was in phase IIb/III trials for the prevention of deep vein thrombosis. By November 2005, a phase III trial had been initiated for the prevention of stroke and embolism due to atrial fibrillation and in May 2006 phase III trials for the prevention of secondary venous thromboembolism began. By July 2007, an EU filing for the drug had been made.
authors.affiliation: Health Sciences University of Hokkaido, Department of Internal Medicine, 1757-Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan. iekom@hoku-iryo-u.ac.jp
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ieko
mesh_terms: D000818:Animals; D001562:Benzimidazoles / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D000069604:Dabigatran; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D015394:Molecular Structure; D010330:Patents as Topic; D011355:Prodrugs / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D011725:Pyridines / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D020521:Stroke / Q000378:metabolism / Q000517:prevention & control*; D013329:Structure-Activity Relationship; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013923:Thromboembolism / Q000378:metabolism / Q000517:prevention & control*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000378:metabolism / Q000517:prevention & control*
chemical_list: D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D011355:Prodrugs; D011725:Pyridines; D013917:Thrombin; D000069604:Dabigatran